|
Nicholas Lydon
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition. Education Lydon was educated at Strathallan School near Perth, Scotland. He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982. Career In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche. Three years later, he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec. In 1997, he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002. T ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Amgen
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.Baker, Pam (2002). ''Thousand Oaks Westlake Village: A Contemporary Portrait''. Community Communications, Inc. Page 37. . Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other pro ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
France
France (), officially the French Republic ( ), is a country primarily located in Western Europe. It also comprises of overseas regions and territories in the Americas and the Atlantic, Pacific and Indian Oceans. Its metropolitan area extends from the Rhine to the Atlantic Ocean and from the Mediterranean Sea to the English Channel and the North Sea; overseas territories include French Guiana in South America, Saint Pierre and Miquelon in the North Atlantic, the French West Indies, and many islands in Oceania and the Indian Ocean. Due to its several coastal territories, France has the largest exclusive economic zone in the world. France borders Belgium, Luxembourg, Germany, Switzerland, Monaco, Italy, Andorra, and Spain in continental Europe, as well as the Netherlands, Suriname, and Brazil in the Americas via its overseas territories in French Guiana and Saint Martin. Its eighteen integral regions (five of which are overseas) span a combined area of and contain clos ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Protein Kinase
A protein kinase is a kinase which selectively modifies other proteins by covalently adding phosphates to them (phosphorylation) as opposed to kinases which modify lipids, carbohydrates, or other molecules. Phosphorylation usually results in a functional change of the target protein ( substrate) by changing enzyme activity, cellular location, or association with other proteins. The human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes. There are two main types of protein kinase. The great majority are serine/threonine kinases, which phosphorylate the hydroxyl groups of serines and threonines in their targets and most of the others are tyrosine kinases, although additional types exist. Protein kinases are also found in bacteria and plants. Up to 30% of all human proteins may be modified by kinase activity, and kinases are known to regulate the majority of cellular pathways, especially those involved in signal transduction. Chemical ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Oncogene
An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.Kimball's Biology Pages. "Oncogenes" Free full text Most normal cells will undergo a programmed form of rapid cell death () when critical functions are altered and malfunctioning. Activated oncogenes can cause those cells designated for apoptosis to survive and proliferate instead. Most oncogenes began as proto-oncogenes: normal genes involved in cell growth and proliferation or inhibition of apoptosis. If, through mutation, normal genes promoting cellular growth are up-regulated (gain-of-function mutation), they will predis ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Modern drug discovery inv ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs arise in the smooth muscle pacemaker interstitial cell of Cajal, or similar cells. They are defined as tumors whose behavior is driven by mutations in the KIT gene (85%), PDGFRA gene (10%), or BRAF kinase (rare). 95% of GISTs stain positively for KIT (CD117). Most (66%) occur in the stomach and gastric GISTs have a lower malignant potential than tumors found elsewhere in the GI tract. Classification GIST was introduced as a diagnostic term in 1983. Until the late 1990s, many non-epithelial tumors of the gastrointestinal tract were called "gastrointestinal stromal tumors". Histopathologists were unable to specifically distinguish among types we now know to be dissimilar molecularly. Subsequently, CD34, and later CD117 were identified as markers that could distinguish the various types. Additionally, in the absence of specific therapy, the diagnostic categ ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes (neutrophils, eosinophils and basophils) and their precursors is found. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is largely treated with targeted drugs called tyrosine-kinase inhibitors (TKIs) which have led to dramatically improved long-term survival rates since 2001. These drugs have revolutionized treatment of this disease and allow most patients to have a good quality of life when compared to the former chemotherapy drugs. In Western countries, CML accounts for 15–25% of all adult leukemias and 14% o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GlaxoSmithKline Prize
The GlaxoSmithKline Prize and Lecture is awarded by the Royal Society of London The Royal Society, formally The Royal Society of London for Improving Natural Knowledge, is a learned society and the United Kingdom's national academy of sciences. The society fulfils a number of roles: promoting science and its benefits, re ... "for original contributions to medical and veterinary sciences published within ten years from the date of the award". Sponsored by GlaxoSmithKline, the medal is awarded with a gift of £2500. The medal was first awarded in 1980 to César Milstein "in recognition of his pioneering the production of monoclonal antibodies from hybrid cell lines and initiating their application worldwide in many fields of biology and medicine", and has since been awarded 13 times. List of recipients SourceRoyal Society See also * List of medicine awards References {{RoySoc Awards of the Royal Society GSK plc Medicine awards Veterinary medicine in the Unite ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Janet Rowley
Janet Davison Rowley (April 5, 1925 – December 17, 2013) was an American human geneticist and the first scientist to identify a chromosomal translocation as the cause of leukemia and other cancers, thus proving that cancer is a genetic disease. Rowley spent the majority of her life working in Chicago and received many awards and honors throughout her life, recognizing her achievements and contributions in the area of genetics. Early life and education Janet Davison was born in New York City in 1925, the only child of Hurford and Ethel Ballantyne Davison. Her father held a master of business administration degree from Harvard Business School, and her mother a master's degree in education from Columbia University. Her parents were educators at the college and high school levels, respectively, and her mother later gave up teaching to become a school librarian. Davison attended an academically challenging junior high school in New Jersey and became especially interested in science. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Charles Sawyers
Charles L. Sawyers (born 1959) is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries. Career Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985, followed by an internal medicine residency at the University of California, San Francisco. He became a HHMI investigator in 2002 while working at UCLA's Jonsson Cancer Center. Sawyers works on molecularly targeted cancer drugs, with a focus on developing a new generation of treatment options for patients. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award with Brian J. Druker and Nicholas Lydon, for the development of the ABL kinase inhibitor imatinib for pati ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Brian Druker
Brian J. Druker (born April 30, 1955) is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award and the Meyenburg Award for his influential work in the development of imatinib for the treatment of chronic myeloid leukemia (CML). He has been called "Oregon's best-known scientist". Education Druker earned both his B.S. degree in chemistry and M.D. degree from the University of California, San Diego. He completed internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984. Teaching and research Druker was a fellow in medical oncology at Dana–Farber Cancer Institute, Harvard Medical School, from 1984 to 1987. He began working at Oregon Health & Science University (OHSU) in 1993. In May ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Lasker-DeBakey Clinical Medical Research Award
Lasker-DeBakey Clinical Medical Research Award is one of four annual awards presented by the Lasker Foundation. The Lasker-DeBakey award is given to honor outstanding work for the understanding, diagnosis, prevention, treatment, and cure of disease. This award was renamed in 2008 in honor of Michael E. DeBakey. It was previously known as the Albert Lasker Award for Clinical Medical Research. List of past winners *1946 John Friend Mahoney, Karl Landsteiner (posthumously), Alexander S. Wiener, Philip Levine *1947 Thomas Francis Jr. *1948 not awarded *1949 Max Theiler, Edward C. Kendall, Philip S. Hench *1950 Georgios Papanikolaou *1951 Élise L'Esperance, Catharine Macfarlane, William G. Lennox, Frederic A. Gibbs *1952 Conrad A. Elvehjem, , H. Trendley Dean *1953 Paul Dudley White *1954 Alfred Blalock, Helen B. Taussig, Robert E. Gross *1955 C. Walton Lillehei, Morley Cohen ( de), , , Hoffmann-La Roche Research Laboratories, Squibb Institute for Medical Research, , Irving ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
